A scintigraphy study of budesonide/glycopyrrolate/formoterol fumarate metered dose inhaler in patients with moderate-to-very severe chronic obstructive pulmonary disease

Table 2 Summary of derived deposition data^a by COPD severity (PP analysis set)

Cohort	Variable	Mean	SD	Median	Min, Max
Overall (N = 17)^b	Emitted dose in lungs, %	32.1	15.6	33.0	6.4, 52.1
	Emitted dose in oropharyngeal + stomach regions, %	67.2	15.1	66.2	47.5, 93.9
	Emitted dose in exhalation filter, %	0.7	0.9	0.5	0.1, 3.8
	Ex-valve dose on actuator, %	11.2	1.7	11.0	9.2, 15.2
	Regional airway deposition ratio:
	O/I	1.04	0.40	1.03	0.34, 1.95
	C/P	0.90	0.69	0.71	0.43, 2.94
	PI	0.55	0.19	0.54	0.17, 0.89
	sC/P	2.21	1.64	1.67	1.13, 7.19
Moderate COPD (N = 9)	Emitted dose in lungs, %	35.2	12.8	41.1	9.3, 52.1
	Emitted dose in oropharyngeal + stomach regions, %	64.3	12.5	58.6	47.5, 89.2
	Emitted dose in exhalation filter, %	0.6	0.4	0.4	0.2, 1.5
	Ex-valve dose on actuator, %	12.0	1.9	11.7	9.9, 15.2
	Regional airway deposition ratio:
	O/I	0.93	0.31	1.03	0.34, 1.46
	C/P	1.01	0.74	0.83	0.48, 2.94
	PI	0.48	0.16	0.49	0.17, 0.74
	sC/P	2.56	1.79	2.03	1.28, 7.19
Severe/very severe COPD (N = 8)	Emitted dose in lungs, %	28.7	18.4	25.5	6.4, 51.5
	Emitted dose in oropharyngeal + stomach regions, %	70.4	17.9	74.0	48.4, 92.9
	Emitted dose in exhalation filter, %	0.9	1.2	0.5	0.1, 3.8
	Ex-valve dose on actuator, %	10.4	1.1	10.2	9.2, 12.7
	Regional airway deposition ratio:
	O/I	1.17	0.48	1.20	0.40, 1.95
	C/P	0.78	0.66	0.54	0.43, 2.37
	PI	0.63	0.20	0.68	0.27, 0.89
	sC/P	1.81	1.45	1.35	1.13, 5.38

^aFollowing a breath-hold of up to 10 s after each inhalation
^bOne patient (with moderate COPD) was excluded due to improper MDI inhalation technique
COPD chronic obstructive pulmonary disease, C/P central to peripheral, MDI metered dose inhaler, Min minimum, Max maximum, O/I outer to inner, PI penetration index, PP per protocol, sC/P standardized central/peripheral, SD standard deviation

ISSN: 1465-993X